Cancer BiologybioRxivPreprint
TALAVE in Breast Cancer: BRCA1/2 Mutation-Dependent Immune Remodeling after PARP Inhibition with Limited Checkpoint Engagement
Filipa C. Lynce, Kaoru Shimada, Claudine J. Isaacs…·Jennifer L. Guerriero
The paper shows BRCA-mutant breast cancers respond to PARP inhibitors with immune remodeling, but PD-L1 blockade is ineffective due to spatial separation of PD-L1+ cells and PD-1+ T cells.
DOI 10.64898/2026.09.17.752386